Interview – TILT on the march
TILT Biotherapeutics Ltd is a Finnish company developing oncolytic virus therapies for cancer. Its lead product, TLT-123 is poised to enter Phase 2 studies in patients with ovarian cancer after having demonstrated that it is safe and able to elicit responses from patients. In an interview, Victor Cervera-Carrascón, the company’s head of business development, gave three reasons why he thought the time is optimal for the biotech industry to pay more attention to oncolytic therapies.
